{"id":252425,"date":"2024-11-21T00:00:00","date_gmt":"2024-11-21T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidon0166-biopharma-neuroendocrine-tumor-epidemiology-americas\/"},"modified":"2026-03-31T10:27:54","modified_gmt":"2026-03-31T10:27:54","slug":"epidon0166-biopharma-neuroendocrine-tumor-epidemiology-americas","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0166-biopharma-neuroendocrine-tumor-epidemiology-americas\/","title":{"rendered":"Neuroendocrine Tumor &#8211; Epidemiology &#8211; Americas"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of neuroendocrine tumors (<abbr title=\"neuroendocrine tumor\">NET<\/abbr>s) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of <abbr title=\"neuroendocrine tumor\">NET<\/abbr>s for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"neuroendocrine tumor\">NET<\/abbr>s forecast will answer the following question:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"neuroendocrine tumor\">NET<\/abbr>s over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS <\/span>Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology forecasts the following <abbr title=\"neuroendocrine tumor\">NET<\/abbr> patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases of <abbr title=\"neuroendocrine tumor\">NET<\/abbr>s.<\/li>\n<li>Diagnosed incident cases of lung <abbr data-abbreviation-entity=\"7746\" title=\"neuroendocrine tumor\">NET<\/abbr>s.<\/li>\n<li>Diagnosed incident cases of gastroenteropancreatic <abbr data-abbreviation-entity=\"7746\" title=\"neuroendocrine tumor\">NET<\/abbr>s (GEP-<abbr data-abbreviation-entity=\"7746\" title=\"neuroendocrine tumor\">NET<\/abbr>s).<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"neuroendocrine tumor\">NET<\/abbr>s.<\/li>\n<li>Diagnosed prevalent cases of lung <abbr data-abbreviation-entity=\"7746\" title=\"neuroendocrine tumor\">NET<\/abbr>s.<\/li>\n<li>Diagnosed prevalent cases of GEP-<abbr data-abbreviation-entity=\"7746\" title=\"neuroendocrine tumor\">NET<\/abbr>s.<\/li>\n<li>Diagnosed incident cases of nonmetastatic <abbr data-abbreviation-entity=\"7746\" title=\"neuroendocrine tumor\">NET<\/abbr>s.<\/li>\n<li>Diagnosed incident cases of metastatic <abbr data-abbreviation-entity=\"7746\" title=\"neuroendocrine tumor\">NET<\/abbr>s.<\/li>\n<li>\u2026 and many more (details available on request).<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-252425","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-solid-tumors","biopharma-product-epidemiology","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/252425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/252425\/revisions"}],"predecessor-version":[{"id":374600,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/252425\/revisions\/374600"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=252425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}